BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LY2127399: Phase III started

Eli Lilly disclosed in its 4Q10 earnings that it began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 90 mg LY2127399 every 2 weeks and 120 mg LY2127399 every 4 weeks for 24 weeks in about 1,002...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >